APLP2
Amyloid beta precursor like protein 2
Also known as: APLP2_HUMAN, APPH, APPL2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q06481
- Gene
- APLP2
- Ensembl
- ENSG00000084234
- Chromosome
- 11
- Canonical length
- 763 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Golgi apparatus,Vesicles
OverviewNCBI Gene
This gene encodes amyloid precursor- like protein 2 (APLP2), which is a member of the APP (amyloid precursor protein) family including APP, APLP1 and APLP2. This protein is ubiquitously expressed. It contains heparin-, copper- and zinc- binding domains at the N-terminus, BPTI/Kunitz inhibitor and E2 domains in the middle region, and transmembrane and intracellular domains at the C-terminus. This protein interacts with major histocompatibility complex (MHC) class I molecules. The synergy of this protein and the APP is required to mediate neuromuscular transmission, spatial learning and synaptic plasticity. This protein has been implicated in the pathogenesis of Alzheimer's disease. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
763 residues, UniProt reviewed canonical sequence.
>Q06481|APLP2
1 MAATGTAAAA ATGRLLLLLL VGLTAPALAL AGYIEALAAN AGTGFAVAEP QIAMFCGKLN
61 MHVNIQTGKW EPDPTGTKSC FETKEEVLQY CQEMYPELQI TNVMEANQRV SIDNWCRRDK
121 KQCKSRFVTP FKCLVGEFVS DVLLVPEKCQ FFHKERMEVC ENHQHWHTVV KEACLTQGMT
181 LYSYGMLLPC GVDQFHGTEY VCCPQTKIIG SVSKEEEEED EEEEEEEDEE EDYDVYKSEF
241 PTEADLEDFT EAAVDEDDED EEEGEEVVED RDYYYDTFKG DDYNEENPTE PGSDGTMSDK
301 EITHDVKAVC SQEAMTGPCR AVMPRWYFDL SKGKCVRFIY GGCGGNRNNF ESEDYCMAVC
361 KAMIPPTPLP TNDVDVYFET SADDNEHARF QKAKEQLEIR HRNRMDRVKK EWEEAELQAK
421 NLPKAERQTL IQHFQAMVKA LEKEAASEKQ QLVETHLARV EAMLNDRRRM ALENYLAALQ
481 SDPPRPHRIL QALRRYVRAE NKDRLHTIRH YQHVLAVDPE KAAQMKSQVM THLHVIEERR
541 NQSLSLLYKV PYVAQEIQEE IDELLQEQRA DMDQFTASIS ETPVDVRVSS EESEEIPPFH
601 PFHPFPALPE NEDTQPELYH PMKKGSGVGE QDGGLIGAEE KVINSKNKVD ENMVIDETLD
661 VKEMIFNAER VGGLEEERES VGPLREDFSL SSSALIGLLV IAVAIATVIV ISLVMLRKRQ
721 YGTISHGIVE VDPMLTPEER HLNKMQNHGY ENPTYKYLEQ MQILocalizationUniProt · AlphaFold · HPA
Whether an antibody against APLP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 570 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 570 nTPM
- retina: 502 nTPM
- choroid plexus: 387 nTPM
- blood vessel: 376 nTPM
- lung: 369 nTPM
- kidney: 336 nTPM
Single-cell type
- neutrophils: 1,391 nCPM
- retinal pigment epithelial cells: 1,364 nCPM
- syncytiotrophoblasts: 1,146 nCPM
- cytotrophoblasts: 1,014 nCPM
- hofbauer cells: 972 nCPM
- alveolar cells type 1: 863 nCPM
Immune cell
- classical monocyte: 249 nTPM
- neutrophil: 161 nTPM
- total PBMC: 149 nTPM
- intermediate monocyte: 122 nTPM
- myeloid DC: 110 nTPM
- non-classical monocyte: 95 nTPM
Brain region
- choroid plexus: 465 nTPM
- cerebellum: 274 nTPM
- thalamus: 269 nTPM
- hypothalamus: 255 nTPM
- cerebral cortex: 255 nTPM
- white matter: 253 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.39
- gnomAD pLI
- 0.38
- gnomAD missense Z
- 0
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- DNA binding
- heparin binding
- identical protein binding
- serine-type endopeptidase inhibitor activity
- transition metal ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Pancreatic trypsin inhibitor Kunitz domain
- Amyloidogenic glycoprotein, extracellular
- Amyloidogenic glycoprotein
- Amyloidogenic glycoprotein, copper-binding
- PH-like domain superfamily
- Amyloidogenic glycoprotein, heparin-binding
- Beta-amyloid precursor protein C-terminal
- Amyloidogenic glycoprotein, copper-binding domain conserved site
- Amyloidogenic glycoprotein, intracellular domain, conserved site
- Proteinase inhibitor I2, Kunitz, conserved site
- Amyloidogenic glycoprotein, E2 domain
- E2 domain superfamily
- Amyloidogenic glycoprotein, heparin-binding domain superfamily
- Amyloidogenic glycoprotein, copper-binding domain superfamily
- Pancreatic trypsin inhibitor Kunitz domain superfamily
- Kunitz/Bovine pancreatic trypsin inhibitor domain
- Amyloid A4 N-terminal heparin-binding
- Beta-amyloid precursor protein C-terminus
- Copper-binding of amyloid precursor, CuBD
- E2 domain of amyloid precursor protein
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of APLP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads APLP2 as an antibody target. Whether an autoantibody or antibody against APLP2 could matter depends on whether native APLP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
APLP2 is annotated at the cell surface, where native APLP2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label APLP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...